454 Life Sciences, a Roche company, and SoftGenetics announced today that the two firms have entered into a copromotion agreement designed to provide users of 454 Sequencing Systems the range of next-generation sequencing data analysis options provided by SoftGenetics’ NextGENe software.
Roche describes the software as being “a free-standing, biologist-friendly software multi-package that is fully compatible with 454 Sequencing data for a wide variety of applications, including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling, and more.”
The software package provides additional options for users of 454 sequencing systems, in addition to the GS Data Analysis Software suite provided with the platforms.
“This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace,” states SoftGenetics co-founder John Fosnacht in a press release. “SoftGenetics welcomes the opportunity to work closely with our colleagues at 454 Life Sciences to provide our mutual customers with integrated sequencing and analysis systems that not only delivers the required quality and sensitivity, but also the efficiency needed in today’s scientific and economic environments.”